It is important to appreciate that the principal issue in this case surrounds the notion of a contract to purchase virtual land. The onus was on Linden Lab to ensure that their online purchasing system was intact and not penetrable to unfair usages by purchasers. On the other hand, it is arguable that Bragg was […]
In 2003, the Tufts Center for the Study of Drug Development (“Tufts”) estimated the cost to develop a new drug to be in excess of $850 million.¦lt;br /> Today, that figure is likely well into the billions. Tufts also found that approximately 20% of new drugs that enter clinical testing eventually receive U.S. marketing approval. […]
India’s rejection of Novartis’ claim on drug improvements highlights the flexibility of India’s patent laws. Such flexibility stands in sharp contrast to the World Trade Organization’s efforts to set standards for intellectual property regulation (via TRIPS agreement) and has enabled India to become a worldwide producer of cheap drugs. Various health agencies have proclaimed the […]
In May of 2007 scientists at J. Craig Venter Institute filed a U.S. patent application on the world’s first synthetic living organism (U.S. Patent application number 20070122826). The patent application claims include a set of essential genes required to provide the bare essentials of life as well as a “free-living organism that can grow and […]
Under traditional legal norms, US patent laws did not extend beyond the territorial bounds of the union. With a quick one-two punch, however, the US court of Appeals for the Federal Circuit (CAFC) has expanded the extraterritorial reach of patent law. I tend to agree with the statement above (from the Article The Expanding Reach […]